Context: Human immunodeficiency virus (HIV) and Hepatitis B virus (HBV) infections are major global public health problems because of their frequency, complications and probable socio-demographic consequences.
Introduction
Human immunodeficiency virus and hepatitis B virus (HIV/HBV) co-infection is common due to similar methods of transmission. Fever and degraded general status were the most frequent signs (65.52%) and (60.34%), respectively, followed by hepatomegaly and jaundice.
More than half of patients were at stages III and IV as per the WHO staging system, respectively (37.93% and 29.31%) ( Table 2) . We noted that (32.04%) were smokers and 12/58 (20.69%) ethyl. Four patients were using hard drug (6.90%) and 30/58 (51.72%) had already developed an opportunistic disease during their progression to antiretroviral therapy (Table 3) . 
Patient Treatment Regimen
Of the 58 patients co-infected with HIV-HBV, 51/58 (87.93%) were under a treatment regimen containing Tenofovir/lamivudine or Tenofovir/Emtricitabine and 7 patients under the lamivudine regimen (Table 4) . Serum creatinine levels were high (≥13 mg/l) in (60.34%) at inclusion and 12/58 (20.6%) after 48 weeks of ARV therapy (p = 0.43) ( Table 5 ). Table 5 . Distribution of patients according to changes in biological parameters at J0; 24 weeks and 48 weeks of antiretroviral therapy
Of the 58 patients enrolled, 2 died during their progression, (3.45%) of lethality.
Discussion
Of the 457 B viral hepatitis tests performed in people living with HIV followed at CTA, from January 1 st 2010 to December 31 st 2014, 58 were positive, (12.7%) of HIV-HBV co-infection prevalence. This is obviously lower than the (16.8%) prevalence found by H. Ndiaye-Diop et al. in Dakar in 2008 (Diop-Ndiaye et al., 2008 , but similar to the prevalence found by Lô et al., in 2012 (Lô et al., 2012 ) (11%) among pregnant women living with HIV in Senegal. This decrease in seroprevalence could be explained by the effectiveness of vaccination against viral hepatitis B in Senegal and the systematic search for HBsAg in the assessment at prenatal consultations.
However, this prevalence corroborates the current global co-infection HIV/HBV trend which is 5-15% worldwide (WHO, 2015) .This is higher than those found in African sources. Tremeau-Bravard, A. et al. in Nigeria in 2012 , Muriuki et al in Kenya in 2013 , Kapembwa et al in Zambia in 2011 (Tremeau-Bravard, Ogbukagu, Ticao, & Abubaka, 2012 Beatrice, Michael, Dorcas, Anthony, & Samoel, 2013; Kapembwa et al., 2011) , who found respectively 7,9%; 6%; 9.9%. On the other hand, Lukhwareni et al. (Lukhwareni, Burnett, Selabe, Mzileni, & Mphahlele, 2009) in South Africa in 2009, found a much higher prevalence than ours (22.9%).
The average age of patients was 39.62 ± 10.12 [21 to 61]. This is higher than the average found in available sources: 34 years in the study of Chloe L. Thio et al. (Thio et al., 2013) , 36 years in that of Attia et al. (Attia et al., 2012) , 32 years in that realized by Yitayih M. et al. (Yitayih, Meseret, Fanaye, & Yeshambel, 2013) , 38 years in the work of H. Diop-Ndiaye et al. (Diop-Ndiaye et al., 2008) . This could be explained by the youth of the overall African population but also by the fact that the population is sexually active at this age. Vol. 9, No. 4; 2017 In our series, there is a slight male predominance (51.17%) with a sex ratio of 1.23.
The predominant character of men in PLHIV with HBV is generally confirmed by the review of the literature. Previous work on the same site showed that men were more concerned than women p = 0. Of the 5639 HIV patients in the study of Jong Hun Kim et al. conducted in the USA, HBsAg seroprevalence was 4.47%. Men were the majority (80.6%). This confirms that the prevalence of HBV in PLHIV is high even in areas of low HBV prevalence (Bado et al., 2013) .
Our results are different from those reported by most African authors who noted a female predominance. This is the case of Chloe L. Thio et al. in a multicentric study (Thio et al., 2013) , G. Bado et al. in Burkina Faso (Kim, Psevdos, Suh, & Sharp, 2008) , Nimzing Gwamzhi Laped et al. in Nigeria (Ladep et al., 2013 ), Yitayih. et al. in Ethiopia (Yitayih, Meseret, Fanaye, & Yeshambel, 2013 and Attia et al. in Cote d'Ivoire, (Attia et al., 2012) .
Monogamous married patients were the most represented group (43.10%), followed by unmarried patients (24.14%).
Our results are similar to those reported by Yitayih W. et al. in 2013 in Ethiopia, 50% and 18% (Yitayih et al., 2013) ; Diombana in 2010 in Mali (Diombana, 2010) who had found 21.18% of unmaried and 19. 53% married.
On the other hand, Walter et al. in 2007 in Italy (Walter & Miele, 2007 found a remarkable predominance of unmaried (51.50%). This difference is related to the fact that the study by Walter R. et al. focused on detainees who were predominantly young and unmarried.
In our series, fever and alteration of the general health conditions were the most visible symptoms with respectively (65.52%) and (60.34%). Ascites, hepatomegaly and jaundice were present in 19, 12 and 6 patients respectively. These results are similar to those found by Diombana S. in 2010 (Diombana, 2010) .
More than half of the patients were included at stages III and II as per the WHO staging system, with (37.93%) and (29.31%) respectively.
Our results are similar to data from available sources, particularly those of DIOMBANA S. in Mali in 2010 (Diombana, 2010) This is due to the fact that patients come to the hospital only at an advanced stage of the disease when symptoms of opportunistic infections appear.
In our series, 24.14% of patients were undernourished (BMI <18.5kg/m²), 15.52% overweight and 3.45% obese. John R. et al. in Rwanda in 2013 (Rusine et al., 2013 found 9.8% undernourished, 32.9% overweight and obese.
Of the 58 patients co-infected with HIV-HBV, 79.31% were on first-line ART containing Tenofovir/lamivudine or Tenofovir/Emtricitabine active for both viruses.
Diombana in Mali in 2010 (Diombana, 2010) 5.36% were actively treated on both viruses.
These contradictory results could be explained by the fact that since 2006, any patient in Senegal with an HIV-HBV co infection is treated with TDF and 3TC or FTC.This is in accordance with the WHO recommendations. As a result, our patients who were not under this regimen were put on 2nd line treatment. The average transaminase (ALT) was 27.22 ± 25.11 IU/l at inclusion. ALT was elevated in 13.52% of cases. Attia et al. in Cote d'Ivoire in 2012 (Attia et al., 2012 , and Van Griensven et al. in Cambodia found lower than ours in 2013 (van Griensven et al., 2014) , with respectively, 8.6% and 3.9% respectively.
Conclusion
The seroprevalence of viral hepatitis B remains relatively high (12.70%) among PLHIV in Dakar. Management of hepatitis B is a challenge due to the lack of public awarness of common symptoms. A low lethality of 3.45% in our patients is noted. Given the results of this descriptive work, it is necessary to conduct a multicenter, in-depth analytical study to better assess not only the profile of HIV-HBV co-infected but also the impact of antiretroviral therapy on the evolution of HBV disease.
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